Review
Copyright ©2014 Baishideng Publishing Group Co.
World J Radiol. Feb 28, 2014; 6(2): 18-25
Published online Feb 28, 2014. doi: 10.4329/wjr.v6.i2.18
Table 1 Prospective clinical trials in the literature studying stereotactic ablative radiotherapy in liver metastases and their results
Ref.DesignNo of patientsTumor sizeSABR doseToxicityOutcomes
Scorsetti et al[15]Phase II (preliminary report)61 (76 tumors)1.8-134.3 cm3 (mean 18.6 cm3)75 Gy in 3 fractionsNo case of RILD. Twenty-six percent had grade 2 transaminase increase (normalised in 3 mo). Grade 2 fatigue in 65% patients, one grade 3 chest wall pain which regressed within 1 year.1-yr LC94, 22-mo LC 90.6%
Goodman et al[16]Phase I (HCC and liver mets)26 (19 liver mets)0.8-146.6 mL (median, 32.6 mL)Dose escalation, 18-30 Gy (1 fr)No dose-limiting toxicity 4 cases of Grade 2 late toxicity (2 GI, 2 soft tissue/rib)1-yr local failure, 3% 2-yr OS, 49% (mets only)
Ambrosino et al[17]Prospective cohort2720-165 mL (median, 69 mL)25-60 Gy (3 fr)No serious toxicityCrude LC rate 74%
Lee et al[18]Phase I-II681.2-3090 mL (median, 75.9 mL)Individualized dose, 27.7-60 Gy (6 fr)No RILD, 10% Grade 3/4 acute toxicity No Grade 3/4 late toxicity1-yr LC, 71% Median survival, 17.6 mo
Rusthoven et al[19]Phase I-II470.75-97.98 mL (median, 14.93 mL)Dose escalation, 36-60 Gy (3 fr)No RILD, Late Grade ¾ < 2%1-yr LC, 95% 2-yr LC, 92% Median survival, 20.5 mo
Høyer et al[10]Phase II (CRC oligomets)64 (44 liver mets)1-8.8 cm (median, 3.5 cm)45 Gy (3 fr)One liver failure, two severe late GI Toxicities2-yr LC, 79% (by tumor) and 64% (by patient)
Méndez Romero et al[20]Phase I-II (HCC and mets)25 (17 liver mets)1.1-322 mL (median, 22.2 mL)30-37.5 Gy (3 fr)Two Grade 3 liver toxicities2-yr LC, 86% 2-yr OS, 62%
Herfarth et al[21]Phase I-II351-132 mL (median, 10 mL)Dose escalation, 14-26 Gy (1 fr)No significant toxicity reported1-yr LC, 71% 18-mo LC, 67% 1-yr OS, 72%